· Regulation · Regulation Desk
For the first time, Medicare Part D covers obesity drugs. The CMS bridge program — negotiated as part of the Trump administration pricing deal with Novo Nordisk and Eli Lilly — takes effect today, extending coverage to an estimated 3–4 million beneficiaries.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.